4.2 Review

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future

Related references

Note: Only part of the references are listed.
Article Psychiatry

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder

Helena A. Gaspar et al.

TRANSLATIONAL PSYCHIATRY (2019)

Review Psychology, Multidisciplinary

Polygenic risk scoring and prediction of mental health outcomes

John S. Anderson et al.

CURRENT OPINION IN PSYCHOLOGY (2019)

Review Biology

A scientometric review of genome-wide association studies

Melinda C. Mills et al.

COMMUNICATIONS BIOLOGY (2019)

Article Clinical Neurology

Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials

Chiara Fabbri et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)

Editorial Material Medicine, General & Internal

Cardiovascular disease: The rise of the genetic risk score

Joshua W. Knowles et al.

PLOS MEDICINE (2018)

Review Neurosciences

The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants

Alessandro Serretti

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2018)

Article Health Care Sciences & Services

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder

Erik J. Groessl et al.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)

Article Clinical Neurology

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings

Alejandra Maciel et al.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2018)

Article Genetics & Heredity

Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores

Kristi Laell et al.

GENETICS IN MEDICINE (2017)

Article Clinical Neurology

Escitalopram plasma levels and antidepressant response

Vincenzo Florio et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)

Review Genetics & Heredity

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

M. Verbelen et al.

PHARMACOGENOMICS JOURNAL (2017)

Article Clinical Neurology

Pharmacogenetics of antidepressant response: A polygenic approach

Judit Garcia-Gonzalez et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)

News Item Multidisciplinary Sciences

New tricks for old drugs

Nicola Nosengo

NATURE (2016)

Article Medicine, General & Internal

Genetic Misdiagnoses and the Potential for Health Disparities

Arjun K. Manrai et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Neurosciences

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

Ajeet B. Singh

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2015)

Review Clinical Neurology

Clinical applications of CYP genotyping in psychiatry

Edoardo Spina et al.

JOURNAL OF NEURAL TRANSMISSION (2015)

Review Health Policy & Services

A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996-2013

David A. Mrazek et al.

PSYCHIATRIC SERVICES (2014)

Review Primary Health Care

Prevalence of treatment-resistant depression in primary care: cross-sectional data

Laura Thomas et al.

BRITISH JOURNAL OF GENERAL PRACTICE (2013)

Review Biochemistry & Molecular Biology

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

Stefano Porcelli et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)